PolyPid 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- For the 3rd quarter of 2026, research and development expenses were $6.5 million, compared to $5.3 million in the 3rd quarter of 2025, primarily due to ongoing NDA-related activities and commercial readiness preparation.
- General and administrative expenses were $1.5 million, compared to $1.8 million in the prior-year period, while marketing and business development expenses were $0.4 million, in line with the prior-year period.
- Net loss for the 3rd quarter of 2026 was $5.8 million, or $0.24 per share, compared to $7.5 million, or $0.37 per share, in the 3rd quarter of 2025; net loss for the first 9 months of 2026 was $21.3 million, or $0.94 per share, compared to $25.7 million, or $1.72 per share, in the same period of 2025.
- As of September 30th, 2026, PolyPid had $15.5 million in cash, cash equivalents, and short-term deposits, compared to $12.9 million at December 31st, 2025; the September 30th balance did not include the $15 million Azurity NDA-acceptance milestone received in early October, which was recorded as a receivable.
- PolyPid said it had received $30 million from its Azurity partnership, with over $290 million in additional development, regulatory, and sales milestones.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Greetings, and welcome to the PolyPid third quarter 2026 conference call. As a reminder, this call is being recorded. I would now like to introduce your host for today's conference, Yehuda Leibler from ARX Investor Relations. Mr. Leibler, you may begin.
Thank you, operator. Thank you all for joining PolyPid's third quarter 2026 earnings conference call. Earlier today, PolyPid released its financial results for the three and nine months ended September 30, 2026. A copy of the press release is available on the investor section of the company's website at www.polypid.com. Joining me on the call today are Dikla Czaczkes Akselbrad, Chief Executive Officer of PolyPid, Ori Warshavsky, Chief Operating Officer U.S. of PolyPid, and Jonny Missulawin, Chief Financial Officer of PolyPid. I'd like to remind you that on this call, management will make forward-looking statements within the meaning of the federal securities laws. These include statements about the FDA's review of the D-PLEX100 NDA, including labeling discussions, the PDUFA goal date, and the FDA pre-approval inspection.
They also cover the potential approval of D-PLEX100 and the anticipated timing of its U.S. commercial launch by Azurity Pharmaceuticals, as well as potential reimbursement for D-PLEX100, including the anticipated timing of a CMS decision on a New Technology Add-on Payment, or NTAP. We will also discuss the potential label expansion of D-PLEX100 and planned communications with the FDA and the EMA's review of the MAA for D-PLEX100, including the anticipated timing of the decision and a potential U.S. launch. In addition, we will refer to the company's plans for Europe, Canada, and other territories, including potential partnerships and their timing. Finally, these statements include the company's PolyPid 2030 vision and levers for growth, the development plans and anticipated timing for PD01B and PD03A, and the company's expectation that its cash resources will be sufficient to fund operations into 2028 and through several significant upcoming potential milestones.
Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond the company's control, including the risks described from time to time in the company's filings with the Securities and Exchange Commission. Accordingly, you should not place undue reliance on these statements. I encourage you to review the company's filings with the SEC, including its annual report on Form 20-F, filed on February 25, 2026. PolyPid disclaims any intention or obligation, except as required by law, to update or revise any forward-looking statements. This conference call contains time-sensitive information that speaks only as of the live broadcast today, November 11, 2026. With that, it's my pleasure to turn the call over to Dikla Czaczkes Akselbrad, Chief Executive Officer of PolyPid.
Dikla? Thank you, Yehuda, and good morning, everyone.
We are now just over two weeks from our PDUFA goal date of November 28th, and this is a defining moment for PolyPid. Let me start with the FDA review. Our NDA for D-PLEX100 for the prevention of surgical site infection in patients undergoing colorectal surgery is under priority review. Since the NDA was accepted in July, we have continued to work closely with the agency. Labeling discussions are underway, and all scheduled FDA interactions are on track and aligned with the PDUFA goal date. As is standard practice, we will not discuss the content of the label ahead of an approval decision. In parallel, PolyPid and Azurity are preparing for the U.S. launch of D-PLEX100 in early 2027, subject to FDA approval, and Ori will walk you through that work.
The partnership has already delivered $30 million to PolyPid, and NTAP application for D-PLEX100 has also been submitted to CMS, with a decision expected in August 2027. If granted, NTAP would provide additional reimbursement to hospital of up to 75% of the product cost above the standard DRG payment. Surgical site infections are not only a colorectal problem, and label expansion is a key growth driver for D-PLEX100. Together with Azurity, our first step is broader abdominal surgery, including GI procedures and hysterectomies, approximately 4 million surgeries a year in the U.S. according to IQVIA. Close to half of them are open procedures. We plan to initiate communications with the FDA on this work in the fourth quarter. Beyond abdominal surgery, we see opportunities in soft tissue and bone surgery. Under our current agreement with Azurity will fund the clinical development once we jointly prioritize indications.
In Europe, we submitted our marketing authorization application to the EMA on September 14, meeting the third quarter timeline we had communicated. Shortly after quarter end, the EMA validated the application and began its formal review, with a decision expected in the second half of 2027 and a potential EU launch in 2028. At the same time, we mutually agreed with ADVANZ PHARMA to terminate our 2022 agreement for Europe, and the exclusive European commercialization rights to D-PLEX100 have revert back to us. We now fully control our European strategy, and we are in active discussions with potential commercial partners. In Canada, part of the Azurity collaboration, a new drug submission is planned for 2027.
At our investor days two weeks ago, we laid out the vision for PolyPid 2030 and our three levers of growth: maximizing D-PLEX100 through Azurity, including label expansion beyond colorectal surgery, taking D-PLEX100 into new territories, starting with Europe, and expanding our Kynatrix pipeline, beginning with PD01B for the treatment of moderate to severe diabetic foot infections, or DFI. D-PLEX100 was always meant to be our first product, not our only one. To summarize the milestone ahead, our PDUFA goal date in two weeks' time on November 28th, the start of FDA communications on broader abdominal surgery this quarter, the U.S. launch of D-PLEX100 in early 2027, subject to approval, the NTAP decision in August 2027, and in the second half of 2027, the EMA decision, as well as the PD01B pre-IND meeting and first-in-human study.
With a committed U.S. partner preparing for launch, full commercialization rights for Europe, a growing pipeline, and a strong balance sheet, we believe PolyPid is well-positioned for this next stage. With that, I will turn the call over to Ori.
Ori? Thank you, Dikla. I will cover our launch preparation with Azurity, new D-PLEX100 data, and our pipeline.
Azurity is an established specialty pharmaceutical company with more than 70 medicines across 11 therapeutic areas, and we believe it is the right partner for D-PLEX100. It brings reach, more than 10 hospital-administered products, more than 200 U.S. commercial-facing colleagues, and the GPO contracting and institutional relationships that reach more than 1,700 leading U.S. hospitals and academic centers. It also brings relevance, a hospital-prescribed antibiotic on the market that gives it credibility with infectious disease specialists and bowel preparation products used by the same colorectal surgeons D-PLEX100 will initially serve. And it brings commitment to invest in and expand the product over time. Since we signed the agreement in July 2026, the work has moved from planning to execution.
Azurity is building out its sales force, national accounts, market access, and medical affairs team, and our companies meet in joint forums across medical, regulatory, supply chain, and commercial functions. We see the commercial launch of D-PLEX100 as a process that will build over several months, starting in early 2027. Subject to approval, Azurity's medical teams will start working with target hospitals, engaging surgeons and infectious disease specialists who can bring D-PLEX100 to the hospital's Pharmacy and Therapeutics, or P&T, committee for review and addition to formulary. Each hospital reviews new products on their own schedule, so access will grow account by account over several months. After the quarter, we also presented D-PLEX100 microbiology data at the IDWeek 2026 conference.
In a late-breaking oral presentation by Dr. George Viola of MD Anderson Cancer Center, an exploratory pooled microbiology analysis of our clinical data covering 2,185 patients looked at infections that occurred despite prevention. The finding from the abstract added microbiologic context to the SHIELD II results. Finally, we introduced PD01B for the treatment of moderate to severe diabetic foot infections at our recent R&D Day. It is our first step in extending Kynatrix from preventing infections to treating them. Diabetic foot infections are among the most serious and costly complications of diabetes, and current treatment relies on debridement and systemic antibiotics, which can struggle to reach adequate concentration in the infected tissue with poor blood supply. PD01B is designed to be applied directly into the wound and to sustain hyper-localized, high doxycycline levels in the infected tissue over weeks.
It builds on the same active ingredient, manufacturing site, and established safety database of D-PLEX100, and PolyPid holds worldwide commercial rights for it. We expect to hold a pre-IND meeting with the FDA and begin a first-in-human study in the second half of 2027. Our long-acting obesity program, PD03A, continues in early preclinical development. With that, I will turn the call over to Jonny to review our financial results.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
10 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
